Clenbuterol for spinal and bulbar muscular atrophy
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests if clenbuterol (a medication that may help strengthen muscles) can improve symptoms in people with spinal and bulbar muscular atrophy (SBMA, also called Kennedy's disease). It compares clenbuterol to a placebo (a dummy pill) over several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man between 18 and 76 years old
- You must have a genetic test confirming you have spinal and bulbar muscular atrophy (SBMA) with at least 38 CAG repeats
- You must have at least one symptom like muscle wasting, limb weakness, or trouble with speech/swallowing (bulbar palsy)
- You must be able to walk on your own, with or without a cane or walker (but not a wheelchair)
- You cannot have heart problems that would make beta2 agonists unsafe, or certain other conditions like glaucoma or severe prostate enlargement
- You must stop taking beta-blockers (if any) for 3 weeks before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether mexiletine hydrochloride can help men with spinal and bulbar muscular atrophy (SBMA) by improving muscle strength and function. It may be an option if you have mild to moderate symptoms and meet heart and medication safety checks.
This study looks for early “biomarkers” (measurable signs) in the body using blood tests, imaging scans, and sometimes other procedures in men with genetically confirmed spinal and bulbar muscular atrophy (SBMA). The results may help future drug studies by showing better ways to track disease changes over time.
This study tests a medication called clenbuterol to see if it can reduce activity of the DUX4 gene, which is believed to cause muscle damage in FSHD. If you have FSHD type 1 or 2, you may be able to join and help researchers understand if this drug can improve muscle health.
This study tests a new oral medication (cladribine) to see if it can reduce muscle weakness and daily symptoms in people with generalized myasthenia gravis. It compares the drug to a placebo (a pill with no active medicine) to check safety and effectiveness.
This pilot trial tests whether a dietary supplement called HMB (beta-hydroxy-beta-methylbutyrate) can help lower a protein called IGFBP7 that may be linked to ALS progression. If it works, this approach might slow down muscle weakness in people with ALS.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
Hear when a new Spinal and Bulbar Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.